中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

34 records (took 0.014 seconds)

    Binding molecule activating FXII
    2.
    发明授权
    Binding molecule activating FXII 有权

    公开(公告)号：US11846641B2

    公开(公告)日：2023-12-19

    申请号：US16622064

    申请日：2018-06-28

    Applicant: Universitätsklinikum Hamburg-Eppendorf

    Inventor： Thomas Renné

    IPC: C07K16/36 ,  G01N33/86 ,  G01N33/68

    CPC classification number: G01N33/86 ,  C07K16/36 ,  G01N33/6854 ,  C07K2317/75

    Abstract: The present invention relates to a binding molecule, in particular an antibody or binding fragment thereof, capable of activating FXII, which binds to the proline rich domain of FXII. In particular, the invention is directed to FXII activating antibodies or binding fragments thereof which binds to the proline rich domain of FXII. The invention also encompasses the use of the binding molecule directed to the proline rich domain of FXII as blood coagulation activator, e.g. in diagnostic blood coagulation tests. Corresponding methods and blood coagulation test are also encompassed.

    MEDICAL TRAINING MODEL HAVING AT LEAST ONE BLOOD VESSEL MODEL
    3.
    发明公开
    MEDICAL TRAINING MODEL HAVING AT LEAST ONE BLOOD VESSEL MODEL 审中-公开

    公开(公告)号：US20230245592A1

    公开(公告)日：2023-08-03

    申请号：US18012562

    申请日：2021-06-08

    Applicant: TECHNISCHE UNIVERSITÄT HAMBURG ,  UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF

    Inventor： Johanna Spallek ,  Juliane VOGT ,  Dieter Krause ,  Jan-Hendrik Buhk ,  Andreas Frölich ,  Jens Fiehler

    IPC: G09B23/28

    CPC classification number: G09B23/286 ,  G09B23/285

    Abstract: Medical training model having at least one blood vessel model (1) which in at least one practice region can be connected to an anatomically replicated substitute blood circulation system (2) and in which a real instrument (17) is used, further having an image recording device (3) for creating measured images of the at least one blood vessel model (1), and having an image processing device (11) which converts the recorded measured images into an imaging blood vessel representation and makes same displayable on a screen (12), wherein the image recording device (3) is designed as a photo-optical system (8) which records transmitted-light images (13) as measured images of the at least one blood vessel model (1) for simulation of medical activity, for which purpose the at least one blood vessel model (1) is replicated in a transparently produced solid-bdy block (4) for a contrast between transparent solid-body block (4) and non-transparent instrument (17).

    ANIMAL MODEL FOR DRUG DEVELOPMENT
    4.
    发明申请
    ANIMAL MODEL FOR DRUG DEVELOPMENT 审中-公开

    公开(公告)号：US20190350178A1

    公开(公告)日：2019-11-21

    申请号：US16479501

    申请日：2018-01-22

    Applicant: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF

    Inventor： Tobias FUCHS ,  Miguel JIMENEZ-ALCAZAR ,  Chandini RANGASWAMY

    IPC: A01K67/027 ,  C07K14/535 ,  A61K49/00 ,  G01N33/50

    Abstract: The present invention relates to a non-human mammalian animal which has been modified to have in the blood, plasma and/or serum (a) an increased number of leukocytes and/or neutrophils, and (b) a reduced activity of the DNase 1 and/or DNase 1-like 3 enzymes. The non-human mammalian animal is particularly suitable for studying inflammation and/or a disease associated with inflammation. In a further aspect, the invention relates to the use of the non-human mammalian animal as a model for identifying therapeutic or diagnostic targets of inflammation and/or a disease associated with inflammation. In a still further aspect, the invention relates the use of the non-human mammalian animal as a model for drug candidate testing. In addition, a method for testing an anti-inflammatory drug candidate against extracellular DNA is provided. Finally, a method for testing an anti-inflammatory drug candidate for modifying the formation or degradation of neutrophil extracellular traps is provided. In still another aspect, the present invention relates to a non-human mammalian animal, which has been modified to have an increased number of neutrophils in blood.

    VIRAL VECTOR FOR THE TARGETED TRANSFER OF GENES IN THE BRAIN AND SPINAL CORD
    5.
    发明申请
    VIRAL VECTOR FOR THE TARGETED TRANSFER OF GENES IN THE BRAIN AND SPINAL CORD 审中-公开
    用于脑和脊髓中基因转移的病毒载体

    公开(公告)号：US20170029464A1

    公开(公告)日：2017-02-02

    申请号：US15303950

    申请日：2015-04-15

    Applicant: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF

    Inventor： Jakob Körbelin ,  Stefan Michelfelder ,  Martin Trepel

    IPC: C07K7/06 ,  C12N7/00 ,  C12N15/86

    CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K48/00 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/14144 ,  C12N2750/14122 ,  C12N2750/14133 ,  C12N2750/14143 ,  C12N2810/6027

    Abstract: The invention relates to novel peptides, polypeptides or proteins which bind specifically to brain cells and/or to the spinal cord. The peptides, polypeptides, or proteins can be components of a viral capsid and can be used to lead a recombinant viral vector selectively to the brain and/or spinal cord after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there. The invention also relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid containing at least one of the claimed peptides, polypeptides, or proteins and which comprises at least one transgene packaged in the capsid. Said viral vector can be used, in particular for the therapeutic treatment of a disease or disorder of the brain and/or spinal cord. The invention further relates to cells and pharmaceutical compositions that comprise the viral vector according to the invention.

    Abstract translation: 本发明涉及特异性结合脑细胞和/或脊髓的新型肽，多肽或蛋白质。 肽，多肽或蛋白质可以是病毒衣壳的组分，并且可以用于在对受试者全身给药后选择性地将重组病毒载体引导至脑和/或脊髓，并确保一个或多个组织特异性表达 转基因在那里 本发明还涉及重组病毒载体，优选AAV载体，其包含含有所要求保护的肽，多肽或蛋白质中的至少一种的衣壳，并且包含至少一种包装在衣壳中的转基因。 所述病毒载体可用于特别是治疗性治疗脑和/或脊髓疾病或病症。 本发明还涉及包含根据本发明的病毒载体的细胞和药物组合物。

    MICRORNA 19A/19B FOR USE IN TREATING A PATHOLOGICAL CONDITION ASSOCIATED WITH BONE LOSS OR REDUCED MUSCLE FUNCTION
    7.
    发明申请
    MICRORNA 19A/19B FOR USE IN TREATING A PATHOLOGICAL CONDITION ASSOCIATED WITH BONE LOSS OR REDUCED MUSCLE FUNCTION 审中-公开

    公开(公告)号：US20200038425A1

    公开(公告)日：2020-02-06

    申请号：US16499520

    申请日：2018-04-06

    Applicant: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF

    Inventor： Eric Hesse ,  Hanna Taipaleenmäki ,  Hiroaki Saito

    IPC: A61K31/711 ,  A61K38/29 ,  A61P19/10

    Abstract: The invention relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with bone loss, in particular osteoporosis and osteogenesis imperfect (01). The inhibitors are also useful for inducing an anabolic effect in bone, either alone or when administered in combination with parathyroid hormone or a recombinant fragment thereof. The invention further relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with reduced muscle function, in particular muscle degeneration and muscle atrophy. The inhibitors are also useful for stabilizing and/or strengthening muscle function. In addition, inhibitors of microRNAs 19a and 19b can be used for treating or preventing cancer-related bone destruction or bone metastasis.

Patent Agency Ranking